|
|
|
SENSEX
|
|
-188.50
|
-0.25%
|
74482.78
|
|
|
NIFTY
|
|
-38.55
|
-0.17%
|
22604.85
|
|
|
Nasdaq
|
|
-325.26
|
-2.04%
|
15657.82
|
|
|
Nikkei 225
|
|
470.90
|
1.24%
|
38405.66
|
|
|
FTSE 100
|
|
-2.90
|
-0.04%
|
8144.10
|
|
|
|
|
|
|
|
|
YOU ARE ON
Equity
|
|
|
|
|
|
|
|
|
29-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding 'Demand Order-In-Original received from Office of Excise and Taxation Officer cum State Tax Officer, Mohali, State Punjab'. |
|
|
|
29-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding 'Demand Order-In-Original received from Office of the Sales Tax Officer, Class-II, State Delhi'. |
|
|
|
27-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication |
|
|
|
26-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 26, 2024, titled "Zydus receives final approval from USFDA for Tretinoin Cream USP, 0.1%". |
|
|
|
25-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding 'Demand Order-In-Original for the financial year 2018-19 on the issue pertaining to Excess Claim of Input Tax Credit received from Office of the Deputy Commissioner, Ghaziabad-I, Uttar Pradesh'. |
|
|
|
24-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding 'Inspection held at the Injectable Manufacturing site situated at Jarod, near Vadodara'. |
|
|
|
23-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange about Loss of Share Certificates |
|
|
|
23-04-2024
|
|
|
ZYDUS LIFESCIENCES LIMITED has informed the Exchange about Loss of share certificates |
|
|
|
23-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 23, 2024, titled "New Drug Application of Zydus innovative drug Desidustat tablets by China Medical System Holdings Limited accepted in China". |
|
|
|
22-04-2024
|
|
|
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 22, 2024, titled "Zydus launches Mirabegron Extended-Release Tablets in the US". |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|